RecruitingPhase 3NCT06464510

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis: An Open-label, Multicenter, Randomized, Controlled Trial: NoVa


Sponsor

Hospital do Coracao

Enrollment

2,800 participants

Start Date

Nov 21, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients with vasopressor dependent sepsis, defined by infection suspicion and antibiotic administration or laboratory confirmed viral infection, plus hypotension with the need of vasopressors for at least one hour;
  • Admitted or expected to be admitted to the ICU in the next 12 hours
  • Adequate volume resuscitation in the opinion of the attending physician
  • Use of norepinephrine > 0.05μg/Kg/min and ≤ 0.25μg/Kg/min for at least 1 hour and at most 24 hours at the time of inclusion

Exclusion Criteria9

  • Use of norepinephrine > 0.25μg/Kg/min in the last 24 hours, except when administered transiently in the context of sedation for a procedure or the initial phase of volume resuscitation for a period of less than one hour
  • Dialysis-dependent chronic kidney disease or acute kidney injury that received renal replacement therapy during current hospitalization or are expected to receive renal replacement therapy in the next 24 hours
  • Use of other vasopressors (except norepinephrine) at the moment of inclusion
  • Use of vasopressors for sepsis in the last 7 days
  • Suspected or confirmed acute mesenteric ischemia
  • Anaphylaxis or known hypersensitivity to the study drug
  • Expect to die in the next 24 hours
  • Medical team not committed to full support at the time of inclusion
  • Previous inclusion in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEarly Vasopressin

Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.

DRUGNorepinephrine and Vasopressin for Rescue

Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.


Locations(8)

Hospital Geral de Caxias do Sul

Caxias do Sul, Rio Grande do Sul, Brazil

Hospital Nereu Ramos

Florianópolis, Santa Catarina, Brazil

Hospital SEPACO

São Paulo, S, Brazil

Hospital de Amor - Unidade Barretos (Fundação PIO XII)

Barretos, São Paulo, Brazil

Hospital do Coracao

São Paulo, São Paulo, Brazil

BP-A Beneficiência Portuguesa de São Paulo

São Paulo, São Paulo, Brazil

Hospital Alemão Oswaldo Cruz

São Paulo, São Paulo, Brazil

Hospital São Paulo - UNIFESP

São Paulo, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06464510


Related Trials